Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Xavier Matias-Guiu x
  • Refine by access: All content x
Clear All Modify Search
Marta Vaquero Department of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Marta Vaquero in
Google Scholar
PubMed
Close
,
Anna Macià Department of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Anna Macià in
Google Scholar
PubMed
Close
,
Carlos Anerillas Department of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Carlos Anerillas in
Google Scholar
PubMed
Close
,
Ana Velasco Department of Pathology, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Ana Velasco in
Google Scholar
PubMed
Close
,
Xavier Matias-Guiu Department of Pathology, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Xavier Matias-Guiu in
Google Scholar
PubMed
Close
,
Joan Ribera Department of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Joan Ribera in
Google Scholar
PubMed
Close
, and
Mario Encinas Department of Experimental Medicine, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain
Department of Pathology, Universitat de Lleida/Institut de Recerca Biomèdica de Lleida, Lleida, Spain

Search for other papers by Mario Encinas in
Google Scholar
PubMed
Close
Free access
Cristina Rodríguez-Antona Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Cristina Rodríguez-Antona in
Google Scholar
PubMed
Close
,
Judith Pallares Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Judith Pallares in
Google Scholar
PubMed
Close
,
Cristina Montero-Conde Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Cristina Montero-Conde in
Google Scholar
PubMed
Close
,
Lucia Inglada-Pérez Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Lucia Inglada-Pérez in
Google Scholar
PubMed
Close
,
Esmeralda Castelblanco Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Esmeralda Castelblanco in
Google Scholar
PubMed
Close
,
Iñigo Landa Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Iñigo Landa in
Google Scholar
PubMed
Close
,
Susanna Leskelä Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Susanna Leskelä in
Google Scholar
PubMed
Close
,
Luis J Leandro-García Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Luis J Leandro-García in
Google Scholar
PubMed
Close
,
Elena López-Jiménez Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Elena López-Jiménez in
Google Scholar
PubMed
Close
,
Rocío Letón Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Rocío Letón in
Google Scholar
PubMed
Close
,
Alberto Cascón Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Alberto Cascón in
Google Scholar
PubMed
Close
,
Enrique Lerma Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Enrique Lerma in
Google Scholar
PubMed
Close
,
M Carmen Martin Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by M Carmen Martin in
Google Scholar
PubMed
Close
,
M Carmen Carralero Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by M Carmen Carralero in
Google Scholar
PubMed
Close
,
Didac Mauricio Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Didac Mauricio in
Google Scholar
PubMed
Close
,
Juan Cruz Cigudosa Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Juan Cruz Cigudosa in
Google Scholar
PubMed
Close
,
Xavier Matias-Guiu Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Xavier Matias-Guiu in
Google Scholar
PubMed
Close
, and
Mercedes Robledo Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain
Hereditary Endocrine Cancer Group, ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Department of Pathology and Molecular Genetics, Pathology Service, Molecular Cytogenetics Group, Department of Endocrinology, Human Cancer Genetics Programme, Spanish National Cancer Center (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain

Search for other papers by Mercedes Robledo in
Google Scholar
PubMed
Close

Therapeutic options for patients with metastatic medullary thyroid carcinoma (MTC) are limited due to lack of effective treatments. Thus, there is a need to thoroughly characterize the pathways of molecular pathogenesis and to identify potential targets for therapy in MTC. Since epidermal growth factor receptor (EGFR) seems to play a crucial role for RET activation, a key feature of MTCs, and several promising EGFR/vascular endothelial growth factor receptor 2 (VEGFR2)-targeted drugs have been developed, the present study was designed to investigate whether these proteins are altered in MTCs. We used a well-characterized series of 153 MTCs to evaluate EGFR activation by sequencing and FISH analysis, and to perform EGFR and VEGFR2 immunohistochemistry. EGFR tyrosine kinase domain mutations were not a feature of MTCs; however, EGFR polysomy and a strong EGFR expression were detected in 15 and 13% of the tumors respectively. Interestingly, EGFR was significantly overexpressed in metastases compared with primary tumors (35 vs 9%, P=0.002). We also studied whether specific RET mutations were associated with EGFR status, and found a decrease in EGFR polysomies (P=0.006) and a tendency towards lower EGFR expression for the most aggressive RET mutations (918, 883). Concerning VEGFR2, metastasis showed a higher expression than primary tumors (P=2.8×10−8). In this first study investigating the relationship between EGFR, RET, and VEGFR2 in a large MTC series, we found an activation of EGFR and VEGFR2 in metastasis, using both independent and matched primary/metastasis samples. This suggests that some MTC patients may benefit from existing anti-EGFR/VEFGR2 therapies, although additional preclinical and clinical evidence is needed.

Free access